FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988632370> ?p ?o ?g. }

• W2988632370 endingPage "3455" @default.
• W2988632370 startingPage "3455" @default.
• W2988632370 abstract "Introduction: Ultrasound (US) assessment of joints is an evolving point of care tool for the detection of early joint arthropathy (Napolitano M, Kessler CM. Hemophilia A and B. Consultative Hemostasis and Thrombosis, Kitchens, 4th edition); population pharmacokinetic (pop-PK) studies are adopted as a useful instrument to set the prophylaxis regimen for patients with hemophilia, they may improve adherence (Nagao A.et al. Thromb Res. 2019 Jan; 173:79-84) and reduce the annual bleeding rate (ABR). Adherence to continuous intravenous administrations of factor VIII or Factor IX products is challenging, thus patients may experience breakthrough bleedings while on prophylaxis. Repeated US examinations of joint status have recently been advocated to attempt to remedy sub-optimal medication adherence (Di Minno A et al., Blood Rev. 2019 Jan;33:106-116). Aim of the current prospective analysis was to evaluate the impact of combined US assessment and pop-PK study on adherence to treatment and health related quality of life in patients with severe hemophilia A(HA) and B (HB) under regular prophylaxis. Material and methods: This prospective observational study was performed at a single tertiary center from January 2017 to June 2019. Research was conducted following the Helsinki Declaration. All patients included in the study provided a written informed consent for study participation. Patients with severe HA and HB routinely underwent, as part of regular 12-months follow-up visits, the following: US joints evaluation of elbows, knees and ankles using the HEAD-US protocol, treatment adherence evaluation by VERITAS-Pro questionnaire, health -related quality of life assessment by the standardized EQ-5D,EQ-VAS and pop-PK study (WAPPS-Hemo, McMaster University) as needed (i.e.in case of changes in life style, planned treatment switch); each patient visualised US and his estimated PK profile during medial encounters. Compliance to the prescribed treatment was also determined by analysis of patient diaries with infusion logs. Statistical analysis was performed using the SPSS software version 25.0 (SPSS Chicago, IL). Statistical tests were 2-sided, with a significance threshold of 0.05. Results: Twenty consecutive males with severe haemophilia were included in the current analysis, 13 with severe HA, 2 with HA with previous inhibitors and 5 HB, with a median age of 30 (range 14- 56) years and a median ABR of 5 (range:0-12). Nine patients were under primary prophylaxis, 8 under secondary prophylaxis and 3 under tertiary prophylaxis, they all self-infused at home. Four patients had one target joint and 3 patients had multiple target joints. For each enrolled subject, HEAD-US score, VERITAS-pro, EQ5D and EQ-VAS score were assessed at enrolment (T0) and at 12 (T12) and 24 (T24) months follow-up visits, respectively. Pop-PK was assessed in 11 patients: in 7 (5 HA,2 HB) it was assessed twice, before and after treatment switch to extended half-life (EHL) products, in 4 it was assessed once to modify prophylaxis treatment schedules for a more active life-style (N=2) or weight changes (N=2). Median ABR was 4 at T12 and 3.8 at T24. Reported breakthrough bleeds at T12 were 14, mainly trauma-related (N= 8) or affecting target joints (N=4), they were not reported at T24 in patients with PK-driven modified schedules (N=4) and in 4 patients under EHL treatments. Mean HEAD-US score at T0 resulted 8 (range:0-16), at T24 it was 6 (range:0-16). Mean Veritas-Pro score values were 42.7 at TO, 40.1 at T12 and 38.7 at T24. At T0, EQ-5D mean utility score was 0.82 (range: 0.68-1), at T24, the mean was 0.87 (range:0.72-1). In detail, at 24 months follow-up, there was a statistically significant (p&lt;0.05) improvement in adherence to treatment with particular reference to the dimensions of communication and skipped doses. A tendency toward improved HEAD-US score, higher adherence and better quality of life scores, was observed in particular in patients switched to EHL products at T24, at a mean of 10 months after switching (range: 6-22 months). Conclusion: Several combined measures of haemophilia treatment monitoring, allowing visual assessment of joints status and PK profile estimates by patients have here shown to improve treatment adherence and quality of life in patients with HA and HB, this may be not only related to new available treatments but also to an increased awareness and education of patients. Disclosures Napolitano: BIOFVIIIx: Consultancy; Novonordisk: Consultancy, Speakers Bureau; Shire: Other: Expert Testimony, Speakers Bureau; Kedrion: Other: Expert Testimony, Speakers Bureau; Octapharma: Speakers Bureau; Bayer: Consultancy, Other: Expert Testimony. Di Minno:Novo Nordisk: Speakers Bureau; CSL: Speakers Bureau; Sanofi: Speakers Bureau; Bayer: Consultancy, Honoraria, Speakers Bureau; Kedrion: Speakers Bureau; Pfizer: Speakers Bureau." @default.
• W2988632370 created "2019-11-22" @default.
• W2988632370 creator A5015461199 @default.
• W2988632370 creator A5026892491 @default.
• W2988632370 creator A5035788601 @default.
• W2988632370 creator A5050997020 @default.
• W2988632370 creator A5069748280 @default.
• W2988632370 creator A5073001267 @default.
• W2988632370 creator A5073490358 @default.
• W2988632370 creator A5085841362 @default.
• W2988632370 creator A5089942437 @default.
• W2988632370 date "2019-11-13" @default.
• W2988632370 modified "2023-10-14" @default.
• W2988632370 title "Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study" @default.
• W2988632370 doi "https://doi.org/10.1182/blood-2019-128129" @default.
• W2988632370 hasPublicationYear "2019" @default.
• W2988632370 type Work @default.
• W2988632370 sameAs 2988632370 @default.
• W2988632370 citedByCount "0" @default.
• W2988632370 crossrefType "journal-article" @default.
• W2988632370 hasAuthorship W2988632370A5015461199 @default.
• W2988632370 hasAuthorship W2988632370A5026892491 @default.
• W2988632370 hasAuthorship W2988632370A5035788601 @default.
• W2988632370 hasAuthorship W2988632370A5050997020 @default.
• W2988632370 hasAuthorship W2988632370A5069748280 @default.
• W2988632370 hasAuthorship W2988632370A5073001267 @default.
• W2988632370 hasAuthorship W2988632370A5073490358 @default.
• W2988632370 hasAuthorship W2988632370A5085841362 @default.
• W2988632370 hasAuthorship W2988632370A5089942437 @default.
• W2988632370 hasBestOaLocation W29886323701 @default.
• W2988632370 hasConcept C126322002 @default.
• W2988632370 hasConcept C141071460 @default.
• W2988632370 hasConcept C142724271 @default.
• W2988632370 hasConcept C159110408 @default.
• W2988632370 hasConcept C1862650 @default.
• W2988632370 hasConcept C187212893 @default.
• W2988632370 hasConcept C188816634 @default.
• W2988632370 hasConcept C204787440 @default.
• W2988632370 hasConcept C23131810 @default.
• W2988632370 hasConcept C2778385053 @default.
• W2988632370 hasConcept C2779526002 @default.
• W2988632370 hasConcept C2779951463 @default.
• W2988632370 hasConcept C2781413609 @default.
• W2988632370 hasConcept C2908647359 @default.
• W2988632370 hasConcept C68122502 @default.
• W2988632370 hasConcept C71924100 @default.
• W2988632370 hasConcept C99454951 @default.
• W2988632370 hasConceptScore W2988632370C126322002 @default.
• W2988632370 hasConceptScore W2988632370C141071460 @default.
• W2988632370 hasConceptScore W2988632370C142724271 @default.
• W2988632370 hasConceptScore W2988632370C159110408 @default.
• W2988632370 hasConceptScore W2988632370C1862650 @default.
• W2988632370 hasConceptScore W2988632370C187212893 @default.
• W2988632370 hasConceptScore W2988632370C188816634 @default.
• W2988632370 hasConceptScore W2988632370C204787440 @default.
• W2988632370 hasConceptScore W2988632370C23131810 @default.
• W2988632370 hasConceptScore W2988632370C2778385053 @default.
• W2988632370 hasConceptScore W2988632370C2779526002 @default.
• W2988632370 hasConceptScore W2988632370C2779951463 @default.
• W2988632370 hasConceptScore W2988632370C2781413609 @default.
• W2988632370 hasConceptScore W2988632370C2908647359 @default.
• W2988632370 hasConceptScore W2988632370C68122502 @default.
• W2988632370 hasConceptScore W2988632370C71924100 @default.
• W2988632370 hasConceptScore W2988632370C99454951 @default.
• W2988632370 hasIssue "Supplement_1" @default.
• W2988632370 hasLocation W29886323701 @default.
• W2988632370 hasLocation W29886323702 @default.
• W2988632370 hasOpenAccess W2988632370 @default.
• W2988632370 hasPrimaryLocation W29886323701 @default.
• W2988632370 hasRelatedWork W1969419914 @default.
• W2988632370 hasRelatedWork W2030548521 @default.
• W2988632370 hasRelatedWork W2311114944 @default.
• W2988632370 hasRelatedWork W2408466823 @default.
• W2988632370 hasRelatedWork W2530190736 @default.
• W2988632370 hasRelatedWork W2788966220 @default.
• W2988632370 hasRelatedWork W2919736625 @default.
• W2988632370 hasRelatedWork W2972984214 @default.
• W2988632370 hasRelatedWork W3023833539 @default.
• W2988632370 hasRelatedWork W3128000855 @default.
• W2988632370 hasVolume "134" @default.
• W2988632370 isParatext "false" @default.
• W2988632370 isRetracted "false" @default.
• W2988632370 magId "2988632370" @default.
• W2988632370 workType "article" @default.